Anlotinib--A “Present” for Treatment of Spinal Epithelioid Hemangioendothelioma: A Case Report and Literature Review

Background: Epithelioid hemangioendothelioma (EHE) is a rare malignant vascular tumor with vascular and sarcomatous components that can affect the spine. There has been no standard second-line treatment for EHE with first-line chemotherapy. Case description: We report a 30-year-old male patient was admitted to our hospital on August 6, 2018.Complaining of waist and lumbar pain lasting for 1 month. Positron emission tomography-computed tomography (PET-CT) showed osteolytic bone destruction and abnormal glucose metabolism and surgically removing the cancer. Post-operative diagnose was EHE. We gave a four-course chemotherapy combination with concurrent radiotherapy. About 1month later, the patients whose cancers have progressed. A second-line treatment is given anlotinib to prevent the further spread of metastatic cancer. Conclusions: : The presence of stable disease after take anlotinib lasted for up to six months and the OS was 16 months. Anlotinib explores therapy in EHE that recoup the defects and shortcomings in rare soft tissue sarcoma. We expect more patients can benefit from this treatment.